Daniel sent us this one, and it's personal. Back around two thousand eight, he came across something called Kratom — obscure, barely on anyone's radar, being sold online with the kind of breathless marketing that makes young people think they've found something ancient and miraculous. Elixir from the far East, all that. He tried it. And then he found out the hard way that getting off it was genuinely awful. His question is: where does global regulation around Kratom actually stand today, and what do we know about what it really does?
Which is a great question to be asking right now, because the regulatory picture is in motion. Like, things shifted in just the last few months in ways that matter.
Before we get into it, by the way, today's episode is powered by Claude Sonnet four point six, which is doing the heavy lifting on the script.
Our friendly AI down the road. Okay, so Kratom. The reason Daniel's experience is such a useful entry point is that it captures exactly the tension at the center of this whole thing. Marketed as natural, marketed as safe, and then the withdrawal hits and you think, wait, what just happened to me.
That gap between the marketing and the reality is, I'd argue, the most dangerous thing about it. Not the plant itself necessarily, but the story being told about it.
And we're going to get into why that story keeps getting told, who benefits from it, and what the science actually says. But before we dive into all that, we should probably start with the basics — what exactly is this plant we're talking about?
Right, because I think a lot of people have heard the name and not much else. Let's actually establish what it is first.
Right, so Mitragyna speciosa is a tree in the coffee family, native to Southeast Asia, Thailand, Malaysia, Indonesia predominantly. And for centuries, workers in those regions would chew the leaves for energy and pain relief. Very practical, very local. Low-dose use was stimulant-like, higher doses became more sedative. It fit into traditional labor culture the same way coca leaves do in parts of South America.
That coca leaf comparison is actually worth sitting with for a second, because it maps pretty cleanly. You've got indigenous populations using a plant in a bounded, culturally understood context — specific amounts, specific purposes, embedded in a social framework that provides its own guardrails. And then it gets extracted from that context, repackaged for a Western market, and the guardrails disappear entirely.
That's exactly the pattern. The coca leaf has been chewed in the Andes for thousands of years with a relatively well-understood risk profile in that context. You extract the active compound, concentrate it, remove the social and cultural scaffolding, and you get cocaine. Kratom didn't go through quite that level of chemical transformation, but the cultural decontextualization is the same move. You strip out the traditional knowledge about dosing and appropriate use, replace it with marketing copy, and sell it to people who have no frame of reference for what they're actually taking.
Then it migrated west.
Gradually, and then very fast. By the mid-two thousands it was showing up in online forums, then supplement shops, and the framing shifted completely. Gone was the agricultural laborer context. Now it was mystical, ancient, a secret the East had been keeping. Which is how Daniel encountered it around two thousand eight.
The elixir pitch.
And the pharmacology is interesting, which is partly why it attracted attention. The two main active compounds are mitragynine and seven-hydroxymitragynine. They act on opioid receptors, particularly the mu-opioid receptor, which is the same receptor targeted by morphine, heroin, oxycodone. Seven-hydroxymitragynine is the more potent of the two and has a significantly higher abuse potential.
When people say it's not an opioid, that's...
Technically true in the sense that it's not derived from the poppy plant. But functionally, at the receptor level, you're activating overlapping pathways. Which is precisely why withdrawal looks so much like opioid withdrawal. Anxiety, muscle aches, cravings. The receptor doesn't care what the molecule's botanical origin story is.
It just knows it's been activated and then it hasn't been.
And that's the core of why it's so polarizing. It does real things. The effects are real. The problem is the story told around it systematically leaves that part out — especially when you consider how dose-dependence complicates the picture.
Right, the dose-dependence makes it weirder still. Because you're not talking about one pharmacological experience. You're talking about two.
That's the thing that trips people up. At low doses, mitragynine behaves more like a stimulant. It's hitting adrenergic receptors, you get increased alertness, more energy, mild euphoria. That's the coffee-family heritage showing through. But as you increase the dose, the opioid receptor activity starts to dominate, and you shift into sedation, analgesia, anxiolysis. Same plant, same compound, completely different experiential profile depending on how much you take.
Which is a nightmare from a dosing standpoint, especially when you're buying something off an early internet marketplace with no standardization whatsoever.
No standardization, no labeling, no idea what concentration you're actually getting. And that's not just a two-thousand-eight problem, we'll get to that. But the mechanism matters here because it explains why people reached for it as an opioid withdrawal tool. If you're coming off heroin or oxycodone, your mu-opioid receptors are screaming. Kratom partially satisfies that signal. It takes the edge off. It's not a complete substitute, but it blunts the worst of it.
The logic isn't crazy on its face.
It's not crazy at all. There was a study published in twenty twenty-three, looked specifically at kratom's efficacy in managing opioid withdrawal symptoms, and the findings were mixed in an interesting way. People reported meaningful reductions in acute withdrawal symptoms. Cravings, muscle discomfort, the anxiety spikes. But the study also flagged that a substantial portion of participants developed what looked like kratom dependence within weeks of using it to manage the original withdrawal.
You traded one problem for a slightly more socially acceptable problem.
With a worse regulatory safety net around it. At least if you're on a methadone program or buprenorphine, there's a clinical framework, there's dosing guidance, there's monitoring. With kratom you're just...
Wait — how does that compare to buprenorphine specifically? Because buprenorphine is also a partial opioid agonist, right? It also works on the mu receptor. Is kratom essentially doing a similar thing, just without the clinical wrapper?
That's a sharp question, and the comparison is instructive. Buprenorphine is a partial agonist, yes, meaning it activates the mu receptor but with a ceiling effect — past a certain dose, the response doesn't increase the way it would with a full agonist like heroin or oxycodone. That ceiling is actually what makes it safer in overdose situations. Kratom's active compounds, particularly seven-hydroxymitragynine, don't appear to have that same ceiling in the same way. And critically, buprenorphine has been through rigorous clinical trials. We know the therapeutic dose range, we know the interaction profile, we know what monitoring looks like. With kratom you have none of that. So yes, mechanistically there are overlapping features, but the difference in what we actually know about safe use is enormous.
Which is essentially what Daniel was doing in two thousand eight, except he wasn't even trying to come off anything. He just encountered it as a supplement and found out the exit was harder than the entrance.
That trajectory is really common. The withdrawal profile is what you'd expect given the receptor activity. You're looking at irritability, insomnia, muscle aches, nausea, the kind of low-grade misery that persists for days. It's not typically life-threatening the way acute opioid withdrawal can be in some contexts, but it is debilitating. People describe it as a particularly bad flu that also makes you emotionally raw.
"Emotionally raw" is doing some work there.
It's the best clinical description I have. The anxiety component is significant. And because kratom has a relatively long half-life compared to something like heroin, the withdrawal can stretch out. You're not through it in forty-eight hours. Some people are dealing with symptoms for a week or more.
The natural framing makes people completely unprepared for that. If you've been told this is an herbal supplement, the equivalent of chamomile tea, and then you stop and feel like that...
The cognitive dissonance is real. And it delays people seeking help because they don't want to tell a doctor they're in withdrawal from a supplement. There's shame attached to it that there maybe wouldn't be if the product had been honest about what it was.
There's actually an interesting parallel there with early energy drink culture, if you think about it. For years those products were marketed as basically glorified juice, and people were surprised when they found out the caffeine content was high enough to cause palpitations or interact badly with certain heart conditions. The "natural" label — taurine, B vitamins, plant extracts — was doing the same kind of softening work. Making something pharmacologically active sound inert.
The energy drink industry eventually got dragged into more disclosure requirements, at least in some markets. But the kratom industry has largely avoided that reckoning so far, partly because the user base is more stigmatized. Nobody's embarrassed to say they had too many energy drinks. Admitting you're in withdrawal from a supplement you bought online carries a different social weight.
The marketing didn't just mislead people about what they were taking. It potentially made recovery harder — something that hasn't been fully acknowledged.
That's a underappreciated harm. The product's framing became an obstacle to treatment.
Let's talk about where regulation has landed, because this is where it gets complicated fast. Different countries are essentially running different experiments simultaneously, with no coordination and wildly different conclusions.
The most striking example is Thailand, which is where a significant portion of the world's kratom grows. Thailand banned it in nineteen forty-three. For decades, possession could get you a prison sentence. And then in twenty twenty-one they reversed course almost entirely, decriminalized it, started framing it as a traditional medicine and an agricultural export opportunity. Complete one-eighty.
The country of origin went from treating it as a controlled narcotic to treating it as a crop.
Driven partly by economics, partly by a genuine reassessment of traditional use, partly by the cannabis legalization wave creating political appetite for rethinking plant-based substances across the board. Indonesia is still the world's largest kratom exporter and it remains in a legal grey zone there, which is a whole separate issue.
How large are we talking, economically? Because I think people underestimate how much money is flowing through this.
It's significant. Indonesia exports somewhere in the range of ten to fifteen thousand tons of kratom annually, and the United States is by far the largest destination market. Some estimates put the US kratom industry at over a billion dollars a year in retail sales. That's not a niche supplement market — that's an industry with real lobbying capacity and a genuine financial interest in keeping the regulatory environment permissive. The American Kratom Association has been quite active in pushing back against FDA scheduling efforts, and they've had some success. That commercial weight is part of why the federal government keeps not quite pulling the trigger on a full scheduling decision.
Which explains some of the inertia. It's not purely scientific uncertainty. There's money on one side of the scale.
There usually is. And then you've got the United States, which has been threatening to do something decisive about kratom for about fifteen years and keeps not quite doing it.
The FDA has issued warnings. Multiple rounds of warnings. They've flagged specific alkaloids, particularly seven-hydroxymitragynine, as having high abuse potential. They've seized shipments. But they haven't scheduled the plant itself under the Controlled Substances Act, and the result is this patchwork where kratom is legal in forty-five states and banned in five, including Alabama and Wisconsin. Rhode Island just moved to permit sales starting April of this year, but added licensing requirements and a specific kratom tax.
The federal government is essentially pointing at it saying "dangerous" while the states make individual calls.
The FDA's current strategy seems to be targeting specific alkaloids rather than whole-leaf products, which leaves a significant loophole. You can still sell kratom powder, kratom capsules, kratom tea. What you theoretically can't do is sell something with concentrated seven-hydroxymitragynine above certain thresholds. Except enforcement is inconsistent at best.
How does that alkaloid-targeting approach actually work in practice though? Because if the compound is naturally present in the plant, how do you draw the line between a whole-leaf product and a concentrated one?
That's exactly the problem. The FDA's position is essentially that products with enhanced or extracted concentrations of seven-hydroxymitragynine cross the line into something more like a drug. But the testing infrastructure to actually verify that at the point of sale doesn't really exist in a systematic way. So you're relying on the seller to not spike their product, which in a grey market is not a guarantee you want to be making.
The European picture is different again.
The European Medicines Agency has not approved kratom for any therapeutic use and generally treats it with significant skepticism, but it's not uniformly banned across the EU either. Individual member states have their own classifications. Sweden and Denmark have restricted it. Others haven't moved. It's not a coherent continental policy.
You can buy it in supplement shops, online, no prescription required, minimal labeling standards. Which sounds permissive until you factor in what that actually means for product quality.
Which brings up the contamination issue, because this isn't just a theoretical risk.
There was a significant incident in Australia in twenty twenty-five involving contaminated kratom products. The details that came out were alarming, not because kratom itself caused the problem, but because the supply chain had essentially no integrity. Products were mislabeled, concentrations were inconsistent, and some were found to contain adulterants. Australia has generally treated kratom as a prohibited import, but that hasn't stopped a grey market, and the grey market produces exactly these outcomes.
You ban it, people still get it, but now there's no accountability anywhere in the supply chain.
That's the knock-on effect that I think gets missed in the regulatory debate. Prohibition doesn't eliminate use, it just removes whatever thin layer of consumer protection existed. A twenty twenty-four analysis found that seventy percent of kratom products sold online contained detectable levels of heavy metals or other contaminants. That's not a fringe problem.
Seventy percent is not a quality control issue. That's a structural failure.
It reflects what happens when a widely used substance exists outside any standardized testing regime. Nobody's checking. The CDC flagged that poison center calls related to kratom surged twelve hundred percent between twenty fifteen and twenty twenty-five. That's not a number you can wave away as anecdote.
To put that in context — a twelve hundred percent increase in poison center calls over a decade, for a substance that's supposedly just a supplement. For comparison, poison center calls related to melatonin, which is one of the most widely used supplements in America, increased around five hundred percent over a similar period, and that generated significant regulatory attention and pediatric safety warnings. Kratom's surge is more than double that rate, and the federal response has been...
The people calling poison control aren't all first-time users who ignored warnings. Some of them thought they were being careful.
Which is the practical implication for anyone engaging with this stuff right now. You do not know what's in the product. You don't know the concentration. You don't know whether what's labeled as plain leaf powder has been spiked with an extract to increase potency, which happens. The absence of standardized dosing isn't just an inconvenience, it's what makes the risk calculus impossible to run accurately.
The natural label does a lot of work to suppress that concern.
It always does. Natural and safe are not synonyms. That's been true of plenty of botanical substances throughout history. Kratom is just a particularly vivid current example — which raises the question: what does this mean for someone considering using it, or already does?
Yeah, that's exactly what I was wondering. So what does any of this mean for someone who's actually thinking about using it, or already is?
The first thing I'd say is, talk to a doctor before you start. I know that sounds obvious, but kratom sits in this gap where people assume because it's sold in a supplement shop, clinical guidance doesn't apply. Especially if you're taking anything else. Kratom interacts with a range of medications, and your prescribing physician almost certainly doesn't know you're using it unless you tell them.
What kind of interactions are we talking about? Because I think people hear "drug interactions" and assume it means mild stuff.
Some of it is mild, but some of it isn't. Kratom is metabolized through the cytochrome P450 enzyme system in the liver — specifically CYP3A4 and CYP2D6. Those same pathways process a huge range of common medications: certain antidepressants, some antihistamines, blood thinners, some antifungals. When two substances are competing for the same metabolic pathway, you can end up with either one building up to unexpectedly high levels in your system, or the other being cleared faster than it should be. If you're on an SSRI and you add kratom to the mix, you've introduced a variable your prescribing doctor didn't account for when they set your dose. That's not theoretical risk, that's a real interaction that's shown up in adverse event reports.
Given that seventy percent of products have contamination issues, you're not even necessarily taking what the label says you're taking.
Which makes the conversation with a doctor even more important, not less. You need someone who can monitor what's actually happening with your liver function, your cardiovascular markers. These are things kratom has been associated with affecting, and you won't catch the early warning signs without baseline labs.
The second piece is the regulatory side, and this is where listeners can actually push on something.
There's a real gap right now between how widely kratom is used and how rigorously products are tested. Advocacy for standardized testing requirements is not a fringe position. If you've had an adverse experience, reporting it to the FDA's MedWatch system or your national equivalent actually feeds into the evidence base that regulators use when they're making scheduling and oversight decisions.
Those reports aren't just bureaucratic noise.
They aren't. They aggregate into the datasets that move policy. The twelve hundred percent surge in poison center calls didn't come from nowhere, and those calls are part of why the FDA's posture has shifted at all.
At minimum, educate yourself from sources that aren't selling you something. The kratom industry has a financial interest in the natural equals safe framing. Peer-reviewed literature does not — and that disconnect is part of why global policies around kratom are such a mess.
And that's what keeps nagging at me. Does any of this actually converge into coherent global policy? Right now you have Thailand pivoting to export, the FDA playing whack-a-mole with specific alkaloids, Canada largely shrugging, and Australia running a prohibition that produces grey markets. Those aren't positions moving toward each other.
They're not even speaking the same regulatory language.
I'm not sure they ever will without a serious multinational research push. The science is still incomplete. We don't have long-term human trial data at the scale you'd need to settle the dependence question definitively, let alone the therapeutic potential question. Until that exists, regulators are making judgment calls in a vacuum, and judgment calls in a vacuum tend to reflect political appetite more than evidence.
Which means the people caught in the middle, the ones using it right now, are essentially running the experiment.
Involuntarily, and without informed consent, because the labeling still doesn't reflect what's actually in the products.
There's a certain irony there, isn't there, in that the therapeutic potential question is the one that could actually justify serious research investment. If kratom compounds really do have a role to play in managing opioid withdrawal — even as a bridge, even in a supervised clinical setting — that's worth knowing properly. But because the substance exists in this regulatory grey zone, the funding and institutional appetite for rigorous trials is limited. You end up in a loop where the uncertainty justifies inaction, and the inaction perpetuates the uncertainty.
That's the loop exactly. And it's not unique to kratom — you see the same dynamic with psilocybin research, with cannabis research before the recent wave of legalization opened things up. Scheduling decisions that were made decades ago on limited evidence end up blocking the very research that would let you revisit those decisions on better evidence. It's a structural problem in how we handle novel or reclassified substances, and kratom is sitting right in the middle of it.
That's where I keep landing. The research will eventually catch up. It always does. The question is how many people have a Daniel-in-two-thousand-eight experience before the framework exists to warn them properly.
That's the open question worth sitting with.
It really is. Thanks to Hilbert Flumingtop for producing, and to Modal for keeping the servers running so we can keep doing this. This has been My Weird Prompts. If the episode was useful, leave us a review wherever you listen.
By the way, today's script was written by Claude Sonnet four point six. The friendly AI down the road, doing its part.
Until next time.
